POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).

How it works

Potassium chloride provides potassium ions for maintenance of electrolyte balance and repolarization of cell membranes. Dextrose 5% provides caloric supplementation and may enhance potassium uptake into cells via insulin-mediated mechanisms. Lactated Ringer's solution provides isotonic crystalloid fluid, electrolytes (sodium, calcium, lactate), and buffer (bicarbonate precursor) to maintain intravascular volume and acid-base balance.

What the body does with it

Metabolism	Potassium is primarily excreted unchanged by the kidneys (90%) and to a small extent via the gastrointestinal tract. Dextrose is metabolized via glycolysis to pyruvate, then enters the citric acid cycle or is stored as glycogen. Lactate is metabolized in the liver to glucose via gluconeogenesis or oxidized in various tissues.
Excretion	Potassium is primarily excreted renally (90%) via glomerular filtration and active secretion in the distal tubule; approximately 10% is lost in feces. In patients with normal renal function, urinary excretion is increased when intake is high. In the presence of renal impairment, elimination is decreased, leading to hyperkalemia risk. Dialysis (hemodialysis or peritoneal dialysis) can remove potassium.
Half-life	Potassium does not have a classical elimination half-life as it is an electrolyte with complex distribution and regulation. After a single IV dose, plasma levels decline rapidly due to redistribution, with an initial distribution half-life of about 1 hour. The terminal phase reflects slow equilibration with total body stores and is influenced by renal function; in anephric patients, the effective half-life is extended significantly.
Protein binding	Potassium is not significantly bound to plasma proteins; it is a free ion. Protein binding is negligible (<1%).
Volume of Distribution	Approximately 0.5-0.7 L/kg, reflecting distribution primarily in the extracellular fluid (ECF) and intracellular uptake. In hypokalemic states, the Vd may be larger due to intracellular depletion. Total body potassium is about 50 mEq/kg, with 98% intracellular.
Bioavailability	Oral potassium chloride: bioavailability is high (approximately 100%) for absorbed formulations, but first-pass extraction is minimal. However, absorption depends on formulation; liquid and effervescent tablets are nearly completely absorbed, whereas enteric-coated or extended-release forms may have slightly lower bioavailability due to incomplete release or binding. Intravenous administration yields 100% bioavailability.
Onset of Action	Intravenous administration: correction of hypokalemia begins within minutes, with maximal effect achieved in 1-2 hours depending on the infusion rate and concentration. Oral administration: onset is delayed, typically 1-2 hours for liquid formulations and 2-4 hours for extended-release tablets.
Duration of Action	Intravenous: duration depends on the underlying deficit; the effect is sustained for several hours after infusion, but continued supplementation may be needed to replete total body stores. Oral: duration of action is related to the rate of absorption and renal elimination; typically, effects last 4-6 hours for immediate-release and up to 12-24 hours for extended-release formulations.

Classification & Brands

Dosing & administration

Intravenous infusion: 10–20 mEq/hour, not to exceed 20–40 mEq in 4 hours or 150 mEq per 24 hours. Rate: max 10 mEq/hour (1 mEq/mL concentration).

Dosage form	INJECTABLE
Renal impairment	GFR > 50 mL/min: no adjustment. GFR 10–50 mL/min: reduce dose by 25–50%, monitor serum potassium. GFR < 10 mL/min: avoid or use extreme caution with close monitoring.
Liver impairment	No specific adjustment for Child-Pugh class A or B. Child-Pugh C: monitor potassium closely due to risk of hyperkalemia.
Pediatric use	0.5–1 mEq/kg/dose IV, not to exceed 3 mEq/kg/day or 40 mEq/m²/day. Infusion rate: max 0.5–1 mEq/kg/hour. Use with dextrose 5% and lactated Ringer's as diluent.
Geriatric use	Start at lower end of dosing range (10 mEq over 4–6 hours), monitor renal function and serum potassium frequently due to age-related decline in GFR and increased risk of hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Breastfeeding	Potassium chloride is a normal plasma component; excretion into milk is proportional to maternal plasma levels. No adverse effects reported. M/P ratio: ~1.
Teratogenic Risk	Potassium chloride is a normal body constituent; no teratogenic risk at therapeutic doses. Dextrose and lactated Ringer's are standard IV fluids. No evidence of fetal harm.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride must be diluted and administered slowly to avoid fatal hyperkalemia and cardiac arrhythmias. Rapid intravenous infusion of concentrated potassium solutions can cause cardiac arrest.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or azotemia","Addison's disease","Acute dehydration","Heat cramps","Patients receiving potassium-sparing diuretics","Hypersensitivity to any component"]

Clinical Precautions

Precautions

["Monitor serum potassium levels frequently during administration","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Severe hyperkalemia can cause muscle weakness, paralysis, life-threatening cardiac arrhythmias, and cardiac arrest","Extravasation may cause tissue necrosis","Not for direct intravenous infusion without proper dilution"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…